Market Overview:
The global direct renin inhibitors (DRIs) market is expected to register a CAGR of 7.5% during the forecast period, 2018-2030. The growth in this market can be attributed to factors such as rising prevalence of hypertension and diabetes, increasing awareness about the benefits of DRIs over ACE inhibitors and ARBs, and technological advancements in DRI development. Based on type, the global DRI market is segmented into aliskiren, remikiren, and others. Aliskiren currently dominates the global DRI market owing to its high efficacy and safety profile as compared to other DRIs available in the market. However, remikiren is expected to grow at a higher CAGR during the forecast period due its potential benefits such as improved renal function parameters and lower incidence of adverse effects as compared to aliskiren.
 Industry Outlook.svg)
Product Definition:
A direct renin inhibitor (DRI) is a drug that blocks the action of the enzyme renin. DRIs are used to lower blood pressure in people with hypertension.
Aliskiren:
Aliskiren is a drug that works by increasing the levels of renin in the body, which ultimately leads to increased blood pressure. Aliskiren has been approved by both the U.S. FDA and European Medicines Agency (EMA) for treatment of hypertension and was designated as a First-Line Therapy (FLT) under EMA’s Generics Program for hypertension due to its cost effectiveness compared to other antihypertensive drugs available at the time of approval.
Remikiren:
Remikiren is used in the treatment of chronic kidney disease patients. It works by reducing the blood flow through kidneys and reduces the production of Renin (renin inhibitor), Angiotensin II, and Aldosterone.
Remikiren Market Size By Route Of Administration (POA), 2012 - 2022 -> The global remikiren market size was valued at USD 648.1 million in 2016.
Application Insights:
The hospital application segment led the market and accounted for more than 69.0% share of the global revenue in 2017. The increasing prevalence of target diseases, such as heart failure, hypertension and diabetes mellitus, is expected to drive the demand for DRI drugs over the forecast period. Moreover, an increase in cardiovascular surgeries is further anticipated to boost product usage in hospital settings during future years.
The others application segment includes surgical oncology and endocrinology applications where direct renin inhibitors are used either alone or in combination with other medications for treatment purposes owing to their better therapeutic outcomes compared with conventional therapy options.
Regional Analysis:
North America dominated the global market in 2017. High prevalence of target diseases such as hypertension, heart failure, and cardiac arrest is one of the major factors responsible for its largest share. Moreover, favorable reimbursement policies for drugs with generic counterparts are also expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to be the fastest-growing region during the forecast period owing to rising healthcare expenditure and increasing patient awareness levels regarding available treatment options. Rising disposable income levels in emerging countries such as China & India are further expected to fuel growth during this period. In addition, an increase in FDA approvals for direct renin inhibitors used across Asia Pacific is also likely boost market development over this period (2016 To 2017). For instance; Eisai Co., Ltd.
Growth Factors:
- Increasing prevalence of hypertension and renal diseases
- Rising geriatric population
- Growing demand for novel therapeutics for the treatment of hypertension and renal diseases
- Technological advancements in the field of DRIs development
- Availability of government funding for research on DRIs
Scope Of The Report
Report Attributes
Report Details
Report Title
Direct Renin Inhibitors (DRIs) Market Research Report
By Type
Aliskiren, Remikiren, Others
By Application
Hospital, Clinic, Others
By Companies
Noden Pharma, LGM Pharma, Cayman, Noden Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Direct Renin Inhibitors (DRIs) Market Report Segments:
The global Direct Renin Inhibitors (DRIs) market is segmented on the basis of:
Types
Aliskiren, Remikiren, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Noden Pharma
- LGM Pharma
- Cayman
- Noden Pharma
 Market Overview.svg)
Highlights of The Direct Renin Inhibitors (DRIs) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Aliskiren
- Remikiren
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Direct Renin Inhibitors (DRIs) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Direct renin inhibitors (DRIs) are medications that block the activity of renin in the body. Renin is a protein that helps to regulate blood pressure and other fluid levels in the body. DRIs can help to reduce blood pressure by reducing the amount of renin produced by the kidneys.
Some of the major companies in the direct renin inhibitors (dris) market are Noden Pharma, LGM Pharma, Cayman, Noden Pharma.
The direct renin inhibitors (dris) market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Direct Renin Inhibitors (DRIs) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Direct Renin Inhibitors (DRIs) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Direct Renin Inhibitors (DRIs) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Direct Renin Inhibitors (DRIs) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Direct Renin Inhibitors (DRIs) Market Size & Forecast, 2020-2028
4.5.1 Direct Renin Inhibitors (DRIs) Market Size and Y-o-Y Growth
4.5.2 Direct Renin Inhibitors (DRIs) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Aliskiren
5.2.2 Remikiren
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Direct Renin Inhibitors (DRIs) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Direct Renin Inhibitors (DRIs) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Aliskiren
9.6.2 Remikiren
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Aliskiren
10.6.2 Remikiren
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Aliskiren
11.6.2 Remikiren
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Aliskiren
12.6.2 Remikiren
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Aliskiren
13.6.2 Remikiren
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Direct Renin Inhibitors (DRIs) Market: Competitive Dashboard
14.2 Global Direct Renin Inhibitors (DRIs) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Noden Pharma
14.3.2 LGM Pharma
14.3.3 Cayman
14.3.4 Noden Pharma
